Sample Illustration of the "CompuSyn Report" of Two-Drug Combinations in Vitro

Similar documents
Assessing drug synergy in combination therapies. Adam Palmer, Ph.D. Laboratory of Systems Pharmacology Harvard Medical School

NIH Public Access Author Manuscript Front Biosci (Elite Ed). Author manuscript; available in PMC 2010 June 15.

Q: How do I get the protein concentration in mg/ml from the standard curve if the X-axis is in units of µg.

Why Using pic50 Instead of IC50 Will Change Your Life

Psychology of Perception Psychology 4165, Fall 2001 Laboratory 1 Weight Discrimination

Psychology of Perception Psychology 4165, Spring 2003 Laboratory 1 Weight Discrimination

Assay Report. Histone Deacetylase (HDAC) Inhibitor Assays Enzymatic Study of Compounds from Client

Toxicity testing. Introduction

The North Carolina Health Data Explorer

To learn how to use the molar extinction coefficient in a real experiment, consider the following example.

Introduction. We can make a prediction about Y i based on X i by setting a threshold value T, and predicting Y i = 1 when X i > T.

Multiple Linear Regression Analysis

UWA ERA Publications Collection 2011

Lesson 2: Describing the Center of a Distribution

Psychology of Perception PSYC Spring 2017 Laboratory 2: Perception of Loudness

LAB ASSIGNMENT 4 INFERENCES FOR NUMERICAL DATA. Comparison of Cancer Survival*

Fructose-6-Phosphate Colorimetric Assay Kit

What Is the Relationship Between the Amount of Transmitted Light Through a Solution and Its Concentration?

Optimization of a LanthaScreen Kinase assay for NTRK1 (TRKA)

Find the slope of the line that goes through the given points. 1) (-9, -68) and (8, 51) 1)

Enzyme Action: Testing Catalase Activity

The MOLECULES of LIFE

Using SPSS for Correlation

Method Comparison Report Semi-Annual 1/5/2018

Understandable Statistics

V. LAB REPORT. PART I. ICP-AES (section IVA)

Essentials in Bioassay Design and Relative Potency Determination

Optimization of a LanthaScreen Kinase assay for ZAP70

Warfarin Help Documentation

Chapter 1: Exploring Data

BlueBayCT - Warfarin User Guide

Enzyme Action: Testing Catalase Activity

Speed Accuracy Trade-Off

Assay Report. Phosphodiesterase (PDE) Inhibitor Assays Enzymatic Study of Compounds from Client

Lab 3: Perception of Loudness

Lab 4 (M13) Objective: This lab will give you more practice exploring the shape of data, and in particular in breaking the data into two groups.

WDHS Curriculum Map Probability and Statistics. What is Statistics and how does it relate to you?

Eileen Crimmins 1 Jianwei Hu 2 Peifeng Hu 3 Wei Huang 2 Jungki Kim 1 Yuhui Shi 2 John Strauss 1 Lu Zhang 1 Xiaohui Zhao 2 Yaohui Zhao 2

Sample Math 71B Final Exam #1. Answer Key

Enzyme Analysis using Tyrosinase. Evaluation copy

Supplementary Figure 1. Basal level EGFR across a panel of ESCC lines. Immunoblots demonstrate the expression of phosphorylated and total EGFR as

Determining the Concentration of Iron in Vitamin Supplements

Lab 4: Perception of Loudness

GLOOKO REPORT REFERENCE GUIDE

ab Cell Invasion Assay (Basement Membrane), 24-well, 8 µm

Unit 1 Exploring and Understanding Data

Use of a camp BRET Sensor to Characterize a Novel Regulation of camp by the Sphingosine-1-phosphate/G 13 Pathway

Behavioral generalization

MULTIPLE LINEAR REGRESSION 24.1 INTRODUCTION AND OBJECTIVES OBJECTIVES

Experiment 1: Scientific Measurements and Introduction to Excel

RNA-Seq Preparation Comparision Summary: Lexogen, Standard, NEB

Clinical Pharmacology. Pharmacodynamics the next step. Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand

What Is the Relationship Between the Amount of Transmitted Light Through a Solution and Its Concentration?

Fully Automated IFA Processor LIS User Manual

Chapter 4: More about Relationships between Two-Variables Review Sheet

bivariate analysis: The statistical analysis of the relationship between two variables.

Preliminary Report on Simple Statistical Tests (t-tests and bivariate correlations)

Supplementary Online Content

Supplementary Figure 1. BMS enhances human T cell activation in vitro in a

Stat 13, Lab 11-12, Correlation and Regression Analysis

Supplementary Figure 1. Metabolic landscape of cancer discovery pipeline. RNAseq raw counts data of cancer and healthy tissue samples were downloaded

Benchmark Dose Modeling Cancer Models. Allen Davis, MSPH Jeff Gift, Ph.D. Jay Zhao, Ph.D. National Center for Environmental Assessment, U.S.

Psychology of Perception Psychology 4165, Spring 2015 Laboratory 1 Noisy Representations: The Oblique Effect

STATISTICS & PROBABILITY

Computer Science 101 Project 2: Predator Prey Model

SUPPLEMENTARY MATERIALS

INRODUCTION TO TREEAGE PRO

Analysis of glipizide binding to normal and glycated human serum Albumin by high-performance affinity chromatography

MALDI Activity 4 MALDI-TOF Mass Spectrometry: Data Analysis

Cell Migration and Invasion Assays INCUCYTE LIVE-CELL ANALYSIS SYSTEM. Real-time automated measurements of cell motility inside your incubator

A statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity

Crystallization-grade After D After V3 cocktail. Time (s) Time (s) Time (s) Time (s) Time (s) Time (s)

Determination of Cannabis Extract Potency Degradation Mechanism and Rate by Infrared Spectroscopy

Optimization of a LanthaScreen Kinase assay for CSF1R (FMS)

Summary of Analytical Method for Quantitative Estimation of Fingolimod and Fingolimod Phosphate from Human Whole Blood Samples

Statistics and Probability

Life History of A Drug

[ APPLICATION NOTE ] High Sensitivity Intact Monoclonal Antibody (mab) HRMS Quantification APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS

NOTE: You must show your work to receive full credit. Simply stating the answer will not suffice.

Chromatography on Immobilized Artificial Membrane

2 Assumptions of simple linear regression

Title:Prediction of poor outcomes six months following total knee arthroplasty in patients awaiting surgery

Astrocyte signaling controls spike timing-dependent depression at neocortical synapses

Lentiviral Delivery of Combinatorial mirna Expression Constructs Provides Efficient Target Gene Repression.

XRDUG Session II Edward Laitila 2/7/2009

OneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use

Nature Neuroscience: doi: /nn Supplementary Figure 1. Behavioral training.

CHAPTER ONE CORRELATION

To open a CMA file > Download and Save file Start CMA Open file from within CMA

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

Quick Start Guide for the CPI Web Training Modules and Assessment FOR NEW USERS

Biology 345: Biometry Fall 2005 SONOMA STATE UNIVERSITY Lab Exercise 5 Residuals and multiple regression Introduction

Section 3 Correlation and Regression - Teachers Notes

ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

IBRIDGE 1.0 USER MANUAL

ACTIVITY USING RATS A METHOD FOR THE EVALUATION OF ANALGESIC. subject and a variety of stimuli employed. In the examination of new compounds

STP 231 Example FINAL

Cancer: A Global View

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1

SUPPLEMENTARY INFORMATION

Transcription:

Sample Illustration of the "CompuSyn Report" of Two-Drug Combinations in Vitro A: Fludelone (FD) in nm (IC 50 was about 2.7 nm), 8 Data Points B: Panaxytriol (PTX) in um (IC 50 was about 3.2 um), 6 Data points [Both drugs have similar numerical value of potency when using unit of nm and um, respectively. So, the constant combination ratio was set arbitrarily at 1:1 (nm : um). ]; 7 Data Points, Mainly with 2-fold serial dilutions, or less than 2-fold dilutions. [For more details see: Zhang N, Fu J, and Chou TC. Am. J. Cancer Research, 2016 (in press)]. [The author s notes are added in the shaded areas on right-side-margin of the CompuSyn Report] CompuSyn Report The analysis usually takes about 1 sec. Printing may take about 1 min. The report contents depend on the selections at the Generate Report command in the menu. Do not use polygonogram since it is for 3 drug combos Experiment Name: FD+PXT in MX-1 in Vitro Date: 9. 15. 2015 Remove * in front of *. cse when give file name for saving File Name: C:\Users\TingChaoChou\Desktop\FD.PXT.MX1. 9.15. 2015.cse Description Combination of Fludelone (PD) and Panaxytriol (PXT) in Vitro against Mammary Cancer MX-1 Cell Growth, XTT assays Drug: Fludelone (FD) [nm] Can be different units. 1nM:1µM in this case. Drug: Panaxytriol (PXT) [µm] If both in µm, then the ratio is 1:1000 Drug Combo: Fludelone + Panaxytriol (FD+PXT) (FD+PXT [1:1]) 1

Data for Drug: FD [nm] Dose Effect 0.05 0.0842 0.125 0.1208 0.25 0.2204 0.5 0.2222 1.25 0.3584 2.5 0.4531 5.0 0.6309 12.5 0.7308 8 data points entered. X-int: 0.43522 Y-int: -0.2693 +/- 0.02517 m: 0.61871 +/- 0.03242 Data points usually from the average Fa values of duplicate or triplicate assays Design Dose Range: Some doses above Dm, and some doses below the Dm value (e.g. here Dm=2.724nm); The approximate Dm value can be from the preliminary data or from published literature Do not enter fa <0.01 or Fa >0.99, unless the assay is very accurate If enter fa=0 or fa=1, the computer will crash The slope "of the median-effect (ME) plot, the dynamic order, or the shape of dose-effect curve; m=1, >1 and <1 indicate Dm: 2.72408 r: 0.99186 Dm: The median effect dose, in this case it is IC 50 value, which indicate potency. The value can be obtained from the X-intercept of the ME-plot r: The linear correlation coefficient of the ME-plot. It signifies the conformity of the data with the mass-action law; an indication of how good are the data, when r=1, it is perfect; For in vitro experiment, usually r>0.95 are considered good or acceptable Data for Drug: PXT [µm] Dose Effect 1.25 0.1305 2.5 0.2697 5.0 0.6349 12.5 0.9812 25.0 0.9949 50.0 0.9993 6 data points entered. X-int: 0.50391 Y-int: -1.3101 +/- 0.16663 m: 2.59980 +/- 0.15768 Dm: 3.19086 r: 0.99272 D 1 has 8 doses (concentrations), and D 2 has 6 concentrations, not the same number is OK as long as they provide m1, (Dm) 1,m 2, and (Dm) 2 values from the dose-effect curves; Most cases, such as 5 vs 5, 6 vs 6 for D 1 and D 2 are OK. The m 1, (Dm) 1 as well as m 2, (Dm) 2 are absolute requirements for determining synergism or antagonism or additive effect since they are required for the calculation of the CI value 2

Data for Drug Combo: FD+PXT (FD+PXT [1:1]) Dose A Effect 0.5+ 0.3218 1.25+ 0.5136 2.5+ 0.6332 5.0+ 0.8777 12.5+ 0.9786 25.0+ 0.9943 50.0+ 0.9995 7 data points entered. X-int: 0.39023 Y-int: -0.6992 +/- 0.22052 m: 1.79184 +/- 0.18016 Dm: 2.45601 r: 0.97565 In this case 1:1 means FD 0.5nM+PXT 0.5uM, etc [NOTES] Recommend to make a 1:1 mixture, and serial dilution them; Do not do more than 2-fold or 3-fold serial dilutions, otherwise the doserange would be too large for the accurate measurements of effects. The constant ratio combination allows computerized simulation of dose-effect curves, Fa-CI effect, Fa-DRI Plot, and isobologram based on the m 1,2 and (Dm) 1,2 values. When combinations are at non-constant ratios, each data point has a ratio, the CI and DRI value can still be calculated, but automated computer simulation can t be carried out; therefore, the acquired conclusions are limited. 3

[NOTES for manual calculation using a pocket calculator] From the above Report, we obtain: m 1 =0.61871, (Dm) 1 =2.72408nM ; m 2= 2.59980, (Dm) 2 =3.19086µM; m 1,2 =1.79184, (Dm) 1,2 =2.45601(1:1)=1.288nM+1.288µM All parameters are calculated from the median-effect principle and equation of the mass-action law f a /f u = (D/D m ) m or D = D m [f a /(1-f u )] 1/m (Chou equation) log (f a /f u ) = m log (D) m log (D m ) Thus, the Median-effect Plot (MEP): x = log(d) y = log(f a /f u ) gives the slope m, and the x-intercept logdm, then the antilog of the X-intercept gives the Dm value. Based on the Combination index Theorem (CIT) and the Median-Effect Equation and Plot, when the combination (D) 1,2 for (D) 1 and (D) 2 is P/Q, we got : Therefore, substituting, the m and Dm parameters, combination ratio P/Q into the corresponding equations given above, and setting fa=0.01-0.99, the CI values at all effect levels can be simulated as Fa-CI table or Fa-CI Plot. The default setting for the CompuSyn is fa=0.05, 0.1, 0.15 0.95 and 0.97 Based on the dose-reduction index (DRI) equations: Similarly, (DRI) 1 and (DRI) 2 values at a particular combination data point can be determined or at different fa value can be simulated. 4

Dose-Effect Curve [NOTES] Due to automated scaling, the dose-effect curves are somewhat jammed. But they are clearly separated after linearization by the media-effect plot ( see below) Median-Effect Plot [NOTES] The slope (m) signifies the shape; The x-intercept (logdm) signifies the potency (the antilog gives the Dm value) 5

CI Data for Drug Combo: FD+PXT (FD+PXT [1:1]) Fa CI Value Total Dose 0.05 10.3965 0.47487 0.1 4.87333 0.72058 0.15 3.11063 0.93284 0.2 2.25725 1.13300 0.25 1.75974 1.33032 0.3 1.43726 1.53062 0.35 1.21357 1.73857 0.4 1.05105 1.95865 0.45 0.92913 2.19580 0.5 0.83565 2.45601 0.55 0.76303 2.74706 0.6 0.70641 3.07967 0.65 0.66262 3.46952 0.7 0.62968 3.94088 0.75 0.60660 4.53425 0.8 0.59342 5.32393 0.85 0.59185 6.46626 0.9 0.60745 8.37107 0.95 0.66132 12.7024 0.97 0.71467 17.0902 CI values for actual experimental points: Total Dose Fa CI Value 1.0 0.3218 0.82116 2.5 0.5136 0.80387 5.0 0.6332 1.01482 10.0 0.8777 0.81016 25.0 0.9786 0.90988 50.0 0.9943 1.07814 100.0 0.9995 0.84229 [NOTES] CI<1, =1, and >1 indicates synergism, additive effect and antagonism, respectively. This is Fa-CI table with Fa increment of 0.05. At fa>0.45 showed synergistic effect (CI<1). For anti-cancer agents, synergism (CI<1) at high dose (high effect) is more relevant to the therapy than the CI values at low dose (low effect). The CI values for each individual combination data point without a simulation 6

Combination Index Plot 1:1 (nm vs µm) Antagonism Synergism [NOTES] Among 7 combination data points 5 of them are on the synergy side (CI<1), the other 2 points are nearly additive The simulation at low fa showed substantial antagonism. This is of less concern since CI values for synergism is 0-1, and for antagonism is 1- ; low fa is less relevant to therapy than high fa (i.e. Killing cancer cells in small fraction is not useful in cancer therapy) Logarithmic Combination Index Plot Antagonism Additive effect Synergism The logarithmic scale for CI values is to condense the graph so if there are out of scale data point can be shown 7

DRI Data for Drug Combo: FD+PXT (FD+PXT [1:1]) Fa Dose FD Dose PXT DRI FD DRI PXT 0.05 0.02336 1.02811 0.09837 4.33008 0.1 0.07815 1.37045 0.21690 3.80375 0.15 0.16506 1.63736 0.35389 3.51047 0.2 0.28982 1.87210 0.51160 3.30468 0.25 0.46139 2.09115 0.69365 3.14384 0.3 0.69258 2.30339 0.90497 3.00974 0.35 1.00160 2.51477 1.15221 2.89292 0.4 1.41452 2.73008 1.44439 2.78772 0.45 1.96953 2.95383 1.79390 2.69044 0.5 2.72408 3.19086 2.21830 2.59841 0.55 3.76772 3.44691 2.74309 2.50953 0.6 5.24604 3.72941 3.40688 2.42195 0.65 7.40878 4.04872 4.27078 2.33388 0.7 10.7144 4.42027 5.43759 2.24329 0.75 16.0833 4.86889 7.09416 2.14761 0.8 25.6042 5.43860 9.61853 2.04308 0.85 44.9573 6.21830 13.9052 1.92331 0.9 94.9582 7.42939 22.6872 1.77501 0.95 317.709 9.90318 50.0234 1.55926 0.97 750.275 12.1503 87.8018 1.42191 DRI values calculated at experimental points Fa Dose FD Dose PXT DRI FD DRI PXT 0.3218 0.81643 2.39536 1.63286 4.79071 0.5136 2.97451 3.25835 2.37961 2.60668 0.6332 6.58349 3.93651 2.63340 1.57460 0.8777 65.8592 6.80979 13.1718 1.36196 0.9786 1313.82 13.8833 105.105 1.11066 0.9943 11437.1 23.2352 457.484 0.92941 0.9995 589141. 59.3678 11782.8 1.18736 DRI >1 and <1 indicate favorable and not favorable dose-reduction; DRI=1 indicates no dose-reduction This is Fa-DRI table with fa increment of 0.05 At 50% inhibition, it requires 2.72408 nm of FD, and requires 3.19086µM of PXT However, it requires 2.2183-fold less FD plus 2.5984-fold less PXT to achieve the same 50% inhibition (i.e., 1.2280nM FD+1.2280µM PXT)(1:1 combination) DRI values of each drug at each combination data point 8

DRI Plot for Combo: FD+PXT (FD+PXT [1:1]) DRI values for FD ( ) and PXT( ) are shown. Most combinations show favorable DRI (>1). The simulation just to show the trends. Favorable DR No Favorable DR Log(DRI) Plot for Combo: FD+PXT (FD+PXT [1:1]) The condensed log(dri) scale Favorable DR No Dose-Reduction Not favorable DR In this case, FD (blue circles) is very potent and toxic; Favorable dosereduction is very beneficial to FD 9

Isobologram for Combo: FD+PXT (FD+PXT [1:1]) Isobologram is for visual, not for quantitative determination of synergism or antagonism. [NOTES] Isobolograms for 50%, 75% and 90% inhibition are shown. There are options in menu to select other fa levels before the beginning of data entries Combination data point on the diagonal line indicates additive effects, on the lower left indicates synergism, on the upper right indicates antagonism. In the present case, IC 90 and IC 75 showed synergism, at IC 50 showed the nearly additive effect. Experiment Name: FD+PXT in MX-1 in Vitro Date: 9. 15. 2015 File Name: Description Summary Table C:\Users\TingChaoChou\Desktop\FD.PXT.MX1. 9.15. 2015.cse Combination of Fludelone (PD) and Panaxytriol (PXT) in Vitro against Mammary Cancer MX-1 Cell Growth, XTT assays Drug: Fludelone (FD) [nm] Drug: Panaxytriol (PXT) [um] Drug Combo: FLudelone + Panaxytriol (FD+PXT) (FD+PXT [1:1]) Most of the contents are used for constructing Table 1. Drug/Combo Dm m r FD 2.72408 0.61871 0.99186 PXT 3.19086 2.59980 0.99272 FD+PXT 2.45601 1.79184 0.97565 CI values at: Combo ED50 ED75 ED90 ED95 FD+PXT 0.83565 0.60660 0.60745 0.66132 For Parameters in Table 1 From the Fa-CI Table of simulation of CI values; For numbers given in CI column of Table 1 (at bottom) 10

Data for Fa = 0.5 Drug/Combo CI value Dose FD Dose PXT FD 2.72408 PXT 3.19086 FD+PXT 0.83565 1.22801 1.22801 Data for Fa = 0.75 Drug/Combo CI value Dose FD Dose PXT FD 16.0833 PXT 4.86889 FD+PXT 0.60660 2.26713 2.26713 Data for Fa = 0.9 Drug/Combo CI value Dose FD Dose PXT FD 94.9582 PXT 7.42939 FD+PXT 0.60745 4.18553 4.18553 Data for Fa = 0.95 Drug/Combo CI value Dose FD Dose PXT FD 317.709 PXT 9.90318 FD+PXT 0.66132 6.35121 6.35121 These data are illustrated for the ED 50 - Isobologram at Fa=0.5 (in Fig. 1d) For DRI at fa=0.5 (bottom of Table 1) for FD=2.72408/1.22801=2.2183 for PXT=3.19086/1.22801=2.5984 For ED 75 -isobologram in Fig. 1d For ED 90 -isobologram in Fig. 1d Synergy (CI<1) at high effect levels (e.g., at fa>0.90) is more relevant to anticancer (therapeutic) effect than the CI at low effect levels (e.g., at fa <0.3) Data for Fa = 0.97 Drug/Combo CI value Dose FD Dose PXT FD 750.275 PXT 12.1503 FD+PXT 0.71467 8.54510 8.54510 11

Supplementary Table1. Citation of Combination Index Method for Synergy Determination Highly Cited Published Paper By T.C. Chou Thomson Reuters Web of Science Citation Data Base* Trends Total Average Citations per 2011 2012 2013 2014 Citations Year Since Publication A. Chou, TC & Talalay, P 289 257 283 324 3,524 110.1 Introduction of Combination Index (CI) / isobologram algorithms Adv. Eng. Regul. 22:27-55, 1984 [2] B. Chou, TC Combination index /isobologram (Review) Pharmacol. Rev. 58: 621-681, 2006 [1] C. Chou, TC Combination Index Method, (FAQ) Cancer Res. 70: 440-446, 2010 [5] 119 146 158 203 968 96.8 41 75 123 173 536 89.3 * Based on Thomson Reuters Web of Science All Database Collection, as of September 28, 2015. 12